NED
REGN icon

Nancy E. Dempze’s Regeneron Pharmaceuticals REGN Stock Holding History

Nancy E. Dempze’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Hold
500
– – 0.15% 72
2026
Q1 		$386K Sell
500
-200
-29% -$153K 0.21% 68
2025
Q4 		$540K Hold
700
– – 0.28% 58
2025
Q3 		$394K Sell
700
-100
-13% -$56.5K 0.22% 66
2025
Q2 		$420K Sell
800
-40
-5% -$22.3K 0.24% 66
2025
Q1 		$533K Sell
840
-120
-13% -$82.5K 0.32% 62
2024
Q4 		$684K Hold
960
– – 0.39% 56
2024
Q3 		$1.01M Sell
960
-140
-13% -$156K 0.56% 49
2024
Q2 		$1.16M Buy
+1,100
New +$1.07M 0.79% 36

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Nancy E. Dempze's REGN Position: Q2 2026 in Review

Nancy E. Dempze held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 500 shares worth $312K. The position accounts for 0.15% of the portfolio, ranked #72.

Nancy E. Dempze first reported a position in REGN in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.16M in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Nancy E. Dempze held 500 shares of Regeneron Pharmaceuticals worth $312K as of Q2 2026.
  • Nancy E. Dempze left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.15% of Nancy E. Dempze's portfolio in Q2 2026, its #72 holding.
  • Nancy E. Dempze first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Nancy E. Dempze's Regeneron Pharmaceuticals position peaked at $1.16M in Q2 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Nancy E. Dempze's 13F filing for Q2 2026, filed 13 Aug 2026.